Audited Financial Results for the Quarter and Year ended on 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.4 pts more than its Diversified Commercial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenlabs Ethica Ltd, a pharmaceutical formulation trader based in Chandigarh, reported audited results for FY25 with revenue from operations of ₹5,142.25 lakhs, down about 12.2% from ₹5,856.31 lakhs in FY24. Profit after tax fell sharply to ₹26.92 lakhs (vs ₹42.12 lakhs, a ~36% decline), translating to basic EPS of ₹0.41 (vs ₹0.65). Q4 FY25 revenue stood at ₹1,298.54 lakhs with PAT of ₹9.07 lakhs, both lower year-on-year. On the balance sheet, total equity improved modestly to ₹1,042.50 lakhs, total borrowings declined to ₹1,187.73 lakhs (D/E ~1.14x), and operating cash flow swung positive to ₹383.13 lakhs from a negative ₹906.07 lakhs last year. The auditor (N. Kumar Chhabra and Co.) issued an unmodified opinion with an Emphasis of Matter on pending confirmation/reconciliation of certain trade receivables, payables and advances.
Topline contraction and sharp PAT decline signal pressure on core operations, which may concern shareholders, though improved operating cash flow and lower debt provide some cushion. The Emphasis of Matter on unconfirmed balances is a minor governance flag to watch.